Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura

References

• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, . Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–7.
   PubMed Web of Science ®Google Scholar
• García-Castro J, Trigueros C, Madrenas J, Pérez-Simón JA, Rodriguez R, Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008;12:2552–65.
   PubMed Web of Science ®Google Scholar
• Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821–7
   PubMed Web of Science ®Google Scholar
• Tabera S, Pérez-Simón J, Díez-Campelo M, Sánchez-Abarca LI, Blanco B, López A, . The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B lymphocytes. Hematologica 2008;93:1301–9
   PubMed Web of Science ®Google Scholar
• Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, . Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214–9
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for the treatment of steroid resistant, severe, acute graft versus host disease: a phase II study. Lancet 2008;371:1579–89.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262:509–25
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De Flora A, . T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005;33:819–27.
   PubMed Web of Science ®Google Scholar
• Jorgensen C, Djouad F, Fritz V, Apparailly F, Plence P, Noël D. Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine 2003;70:483–5.
   PubMed Web of Science ®Google Scholar
• Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, . Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro . Rheumatology 2007;46:403–8.
   PubMed Web of Science ®Google Scholar
• Gordon D, Pavlowska G, Glover C, Uney J, Wraith D, Scolding N. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett 2008;448:71–3.
   Google Scholar
• Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, . Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008;112:1325–8.
   PubMed Web of Science ®Google Scholar
• Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+ Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high dose dexamethasome. Eur J Haematol 2007;79:310–16.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, . Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007;78:139–43.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815–22.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, . MSC in human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 2008;26:212–22.
   PubMed Web of Science ®Google Scholar
• Pérez-Ilzarbe M, Díez-Campelo M, Aranda P, Herrero-Sánchez C, Tabera S, Lopez T, . Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy (MSC). Transfusion 2009
   PubMedGoogle Scholar
• Villarón EM, Pérez-Simón JA, San Miguel JF, Del Cañizo C. Bone marrow mesenchymal stem cell chimerism after allogeneic hematopoietic transplantation. Exp Hematol 2006;34:7.
   PubMedGoogle Scholar
• Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, . Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia 2003;17:2318–57.
   PubMed Web of Science ®Google Scholar
• Kang YJ, Jeon ES, Song HY, Woo JS, Jung JS, Kim YK, . Role of c-Jun N-terminal kinase in the PDGF-induced proliferation and migration of human adipose tissue-derived mesenchymal stem cells. J Cell Biochem 2005;95:1135–45.
   PubMed Web of Science ®Google Scholar
• Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, . Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005;205:228–36.
   PubMed Web of Science ®Google Scholar
• García-Castro J, Trigueros C, Madrenas J, Pérez-Simón JA, Rodriguez R, Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008;12:2552–65.
   PubMed Web of Science ®Google Scholar
• Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, . Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008;181:3933–46.
   PubMed Web of Science ®Google Scholar
• Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991;78:2619–25.
   PubMed Web of Science ®Google Scholar
• Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, . Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245–54.
   PubMed Web of Science ®Google Scholar
• Nguyen H, Gitig D, Koff A. Cell-free degradation of p27kip1, a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 1999;19:1190–201.
   PubMed Web of Science ®Google Scholar
• Blain SW. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 2008;7:892–8.
   PubMed Web of Science ®Google Scholar